Skip to main content
Log in

Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: Data from the GH Registry

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: The aim of this study is to estimate the annual incidence and prevalence rate of the GH treatment exposure in patients under the age of 18 treated for hypopituitarism or isolated GH deficiency (GHD) in Piedmont, during the period January 1, 2002 to December 31, 2004. Methods: The selection criteria for recombinant human GH (rhGH) treatment in childhood were approved by the Ministry of Health in Italy in the yr 1998. The present analysis is based on data from the Registry of subjects receiving GH therapy (GH Registry) made up of the 918 pediatric patients (age <18 yr) with a diagnosis of GHD (excluding Prader-Willi and Turner syndromes and other conditions), diagnosed in the period January 1, 2002–December 31, 2004. The case series has been described as regards the number of cases per year of diagnosis; the prevalence and incidence rates, calculated per 10,000 (‱) inhabitants, are given for each year of the study period. Results: The prevalence rate increases slightly from 8.62‱ in 2002 to 9.44‱ in 2004 and the incidence rates estimated were 2.49‱, 1.86‱ and 1.97‱ in the yr 2002, 2003 and 2004, respectively. Conclusion: The Piedmont GH Registry represents the first database available in Italy and could set an example for the other Italian regions as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. GH Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998, 83: 379–81.

    Google Scholar 

  2. GH Research Society. Consensus guidelines forthe diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 2000, 85: 3990–3.

    Google Scholar 

  3. Erfurth EM, Bengtsson BA, Christiansen JS, Bulow B, Hagmar L. Premature mortality and hypopituitarism. Lancet 2001, 357: 1972–4.

    Article  CAS  PubMed  Google Scholar 

  4. Bulow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM. High incidence of mental disorders, reduced mental well-being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease. Clin Endocrinol (Oxf) 2002, 56: 183–93.

    Article  Google Scholar 

  5. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46: 75–81.

    Article  CAS  Google Scholar 

  6. Wyatt D. Lessons from the national cooperative growth study. Eur J Endocrinol 2004, 151(Suppl 1): S55–9.

    Article  CAS  PubMed  Google Scholar 

  7. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 2005, 84: 4307–16.

    Article  Google Scholar 

  8. Ranke MB, Wilton P. Growth hormone therapy in KIGS-10 years’ experience. Barth Verlag Heidelberg Leipzig 1999, 10–20.

  9. Parkin JM. Incidence of growth hormone deficiency. Arch Dis Child 1974, 49: 904–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994, 125: 29–35.

    Article  CAS  PubMed  Google Scholar 

  11. Thomas M, Massa G, Craen M, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986–2001. Eur J Endocrinol 2004, 151: 67–72.

    Article  CAS  PubMed  Google Scholar 

  12. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001, 55: 735–40.

    Article  CAS  Google Scholar 

  13. Coste J, Letrait M, Carel JC, et al. Long-term results of growth hormone treatment in France in children of short stature: population, register based study. BMJ 1997, 315: 708–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Gazzetta Ufficiale n. 7 del 10 gennaio 2001 — Ministero della Sanità.

  15. Altman DG, Machin D, Bryant T, Gardner MJ. Statistics with confidence. Bristol: BMJ Books. 2000.

    Google Scholar 

  16. La Banca Dati Demografica Evolutiva della Regione Piemonte: http://www.regione.piemonte.it/stat/bdde/index.htm

  17. Supplemento ordinario alla “Gazzetta Ufficiale” no 259 del 4 novembre 2004-Ministero della Sanità; Note AIFA 2004 (Revisione Note CUF).

  18. NOTE AIFA - http://www.simg.it/news/farmaco/note/Note_Aifa_2004.pdf

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G. Migliaretti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Migliaretti, G., Aimaretti, G., Borraccino, A. et al. Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: Data from the GH Registry. J Endocrinol Invest 29, 438–442 (2006). https://doi.org/10.1007/BF03344127

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344127

Key-words

Navigation